



Contact: Dale R. Heffler
(908) 731-6605
dheffler@njhf.org

For Immediate Release
November 7, 2013

Actinobac Biomed Founder Receives Two Awards For Promising New Drug

New Brunswick, NJ – Scott Kachlany, PhD, founder of Actinobac Biomed, Inc., has received a Thomas Edison Patent of the Year Award from the Research and Development Council of New Jersey and an Innovators Award from the New Jersey Inventors Hall of Fame for his renowned research in discovering new agents in the treatment of leukemias.

Dr. Kachlany, an associate professor of oral biology, microbiology and molecular genetics at Rutgers Dental School of Medicine, discovered the therapeutic uses of Leukothera[®] during the course of his research at the dental school. His company, Actinobac Biomed, was originally funded with a \$500,000 investment in 2009 from Foundation Venture Capital Group (FVCG), LLC. , which invested an additional \$100,000 in Actinobac in 2013 to help advance its research.

Leukothera is being tested as a treatment for hematologic malignancies (leukemias & lymphomas), latent infections (HIV/AIDS & tuberculosis) and autoimmune diseases (rheumatoid arthritis, multiple sclerosis, Crohn’s disease, type 1 diabetes, Lupus & psoriasis).

“We are gratified that others recognize the exciting potential in Dr. Kachlany’s work,” said George F. Heinrich, M.D., vice chair and CEO of Foundation Venture Capital Group, “and we join the Research and Development Council of New Jersey and the New Jersey Inventors Hall of Fame in acknowledging the importance of his work.”

Leukothera® specifically targets and depletes disease related white blood cells (WBC). In laboratory studies to date, malignant and proinflammatory white blood cells have been determined to be more sensitive to Leukothera® than normal white blood cells. Animal studies carried out by Actinobac have shown Leukothera® to possess significant therapeutic activity.

For more information contact James M. Golubieski, president of Foundation Venture Capital Group, at jgolubieski@njhf.org or visit www.foundationventure.com.